Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
What microdosing does not do reliably is deliver the 15 percent+ weight loss you see in the STEP trials
Phase 2 showed 24.2% weight loss at 48 weeks
In recent years, GLP-1 receptor agonists have emerged as a powerful tool for improving metabolic health, gaining widespread attention for their ability to help reduce excess body fat
But until now, they have largely been available in the U.S
Take a look at our menus to see delicious choices for breakfast, lunch, and dinner fully prepared and ready to eat
.jpeg)
